Dario Amodei is right that capability-tiered testing isn't regulatory capture, it's a tax on being biggest. But investor David Sacks has a real counter: that same tax only holds if smaller labs actually clear the queue faster, and neither Amodei nor Gavin Baker is asking whether any lab can prove its safety claims at all.
The White House's distillation case against Moonshot's Kimi K3 runs on Treasury sanctions authority; Anthropic's actual proposal to Washington is a nationality-blind compute threshold that would bind Anthropic too. The two get confused often, and they aren't the same lever. Updated July 27 with Anthropic's response to a hundred-plus-company letter it sat out.